23 September 2021 - Early treatment study
Safety and efficacy of a MEURI Program for the use of high dose ivermectin in COVID-19 patients
et al., Zenodo, doi:10.5281/zenodo.5525362 (Preprint)
Retrospective 21,232 patients in Argentina, 3,266 assigned to ivermectin treatment, showing lower mortality with treatment. Greater benefits were seen for patients >40, and a dose dependent response was found.
|
risk of death, 55.1% lower, RR 0.45, p < 0.001, treatment 3,266, control 17,966, adjusted per study, odds ratio converted to relative risk, multiple logistic regression, Figure 3.
|
|
risk of ICU admission, 65.9% lower, RR 0.34, p < 0.001, treatment 3,266, control 17,966, adjusted per study, odds ratio converted to relative risk, multiple logistic regression, Figure 3.
|
|
risk of death, 27.6% lower, RR 0.72, p = 0.03, treatment 3,266, control 17,966, odds ratio converted to relative risk, unadjusted.
|
|
risk of ICU admission, 26.0% lower, RR 0.74, p = 0.13, treatment 3,266, control 17,966, odds ratio converted to relative risk, unadjusted.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Mayer et al., 9/23/2021, retrospective, Argentina, South America, preprint, 14 authors, dosage 540μg/kg days 1-5, mean prescribed dose.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.